Phase 2 study of PB1046 for the treatment of pulmonary arterial hypertension (PAH)
Phase of Trial: Phase II
Latest Information Update: 29 Nov 2017
At a glance
- Drugs PB 1046 (Primary)
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- 29 Nov 2017 Planned initiation date changed from 1 Jan 2017 to 1 Jan 2018, as reported in a PhaseBio Pharmaceuticals media release.
- 29 Nov 2017 According to a PhaseBio Pharmaceuticals media release, this trial is expected to initiate in 2018.
- 20 Jan 2017 New trial record